|
CN100406567C
(zh)
*
|
2002-01-22 |
2008-07-30 |
生物材料公司 |
生物可降解聚合物的干燥方法
|
|
EP1846401B1
(en)
*
|
2005-02-04 |
2008-06-18 |
CTG Pharma S.r.l. |
New 4-aminoquinoline derivatives as antimalarials
|
|
PL1879573T3
(pl)
|
2005-05-10 |
2013-05-31 |
Incyte Holdings Corp |
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
US8450351B2
(en)
*
|
2005-12-20 |
2013-05-28 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
US20080146624A1
(en)
*
|
2006-09-19 |
2008-06-19 |
Incyte Corporation |
Amidines as modulators of indoleamine 2,3-dioxygenase
|
|
WO2008036642A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
WO2008058178A1
(en)
*
|
2006-11-08 |
2008-05-15 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
JP5465720B2
(ja)
|
2008-07-08 |
2014-04-09 |
インサイト・コーポレイション |
インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
|
|
KR20150087400A
(ko)
|
2012-11-20 |
2015-07-29 |
버텍스 파마슈티칼스 인코포레이티드 |
인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
|
|
KR102271498B1
(ko)
|
2013-08-30 |
2021-07-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
종양 치료를 위한 키누레닌 고갈 효소의 투여
|
|
ES2799582T3
(es)
|
2013-11-08 |
2020-12-18 |
Incyte Holdings Corp |
Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
|
|
KR102457145B1
(ko)
|
2013-12-24 |
2022-10-19 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 트리시클릭 화합물
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
EP3186371B1
(en)
|
2014-08-29 |
2024-08-14 |
Board of Regents, The University of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
AU2015349878A1
(en)
|
2014-11-21 |
2017-05-25 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
EA037112B1
(ru)
|
2015-03-02 |
2021-02-08 |
Ригель Фармасьютикалс, Инк. |
Ингибиторы tgf-
|
|
KR20170134981A
(ko)
|
2015-04-03 |
2017-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
AU2016249981B2
(en)
|
2015-04-13 |
2022-02-17 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
US10683290B2
(en)
|
2015-05-11 |
2020-06-16 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
ES2770349T3
(es)
|
2015-05-12 |
2020-07-01 |
Bristol Myers Squibb Co |
Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
|
CN108349976A
(zh)
|
2015-08-25 |
2018-07-31 |
百时美施贵宝公司 |
TGFβ受体拮抗剂
|
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
MX2018006181A
(es)
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
|
|
JP6856648B2
(ja)
|
2015-12-15 |
2021-04-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｘｃｒ４受容体アンタゴニスト
|
|
WO2017140835A1
(en)
|
2016-02-19 |
2017-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
EP3423483B1
(en)
|
2016-03-02 |
2025-09-24 |
Board Of Regents Of the University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
EP3423494A1
(en)
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
EP3452450A1
(en)
|
2016-05-04 |
2019-03-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR20190004743A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
WO2017192840A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2017192844A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
US11351164B2
(en)
|
2016-08-26 |
2022-06-07 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
UY37466A
(es)
|
2016-11-03 |
2018-01-31 |
Phenex Discovery Verwaltungs Gmbh |
N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
|
|
CN114989205A
(zh)
|
2016-12-22 |
2022-09-02 |
卡里塞拉生物科学股份公司 |
用于抑制精氨酸酶活性的组合物和方法
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
CA3047002A1
(en)
|
2017-01-17 |
2018-07-26 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
CA3057312A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Merck Sharp & Dohme Corp. |
Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
CN110709420A
(zh)
|
2017-03-31 |
2020-01-17 |
戊瑞治疗有限公司 |
使用抗gitr抗体的癌症组合疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
KR20190139216A
(ko)
|
2017-04-28 |
2019-12-17 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR101965348B1
(ko)
*
|
2017-06-26 |
2019-04-03 |
한국화학연구원 |
N'-히드록시인다졸카르복시이미다미드 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염, 및, 이를 유효성분으로 포함하는 항암용 조성물
|
|
WO2019003142A1
(en)
*
|
2017-06-28 |
2019-01-03 |
Glaxosmithkline Intellectual Property Development Limited |
MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
|
|
CN110709391A
(zh)
*
|
2017-06-28 |
2020-01-17 |
葛兰素史克知识产权开发有限公司 |
吲哚胺2,3-双加氧酶的调节剂
|
|
EP3644993B1
(en)
|
2017-06-30 |
2023-08-02 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of ido inhibitors
|
|
JP7186764B2
(ja)
|
2017-07-28 |
2022-12-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
BR112020003116A2
(pt)
|
2017-08-17 |
2020-08-04 |
Ikena Oncology, Inc. |
inibidores de ahr e usos dos mesmos
|
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
US10947263B2
(en)
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
KR102812783B1
(ko)
|
2017-08-31 |
2025-05-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
US11053230B2
(en)
|
2017-09-01 |
2021-07-06 |
Netherlands Translational Research Center B.V. |
3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US11660311B2
(en)
|
2017-10-10 |
2023-05-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
EP3697801B1
(en)
|
2017-10-16 |
2024-11-20 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019115586A1
(en)
|
2017-12-12 |
2019-06-20 |
Phenex Discovery Verwaltungs-GmbH |
Oxalamides as modulators of indoleamine 2,3-dioxygenase
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
ES2980374T3
(es)
|
2018-03-08 |
2024-10-01 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
EP3774755B1
(en)
|
2018-03-29 |
2022-05-18 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
BR112020020772A2
(pt)
|
2018-04-16 |
2021-02-02 |
Board Of Regents, The University Of Texas System |
enzimas quinureninase humana e usos das mesmas
|
|
JP2021522211A
(ja)
|
2018-04-16 |
2021-08-30 |
アリーズ セラピューティクス， インコーポレイテッド |
Ｅｐ４阻害剤およびその使用
|
|
WO2019206800A1
(en)
|
2018-04-24 |
2019-10-31 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
|
CN112585139B
(zh)
|
2018-06-27 |
2023-12-01 |
百时美施贵宝公司 |
用作t细胞激活剂的萘啶酮化合物
|
|
KR102767739B1
(ko)
|
2018-06-27 |
2025-02-12 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
|
|
CN113056483B
(zh)
|
2018-07-09 |
2025-08-01 |
戊瑞治疗有限公司 |
结合到ilt4的抗体
|
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
|
WO2020018670A1
(en)
|
2018-07-17 |
2020-01-23 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
|
CN113316590B
(zh)
|
2018-11-16 |
2025-02-28 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
|
US12012374B2
(en)
|
2019-05-13 |
2024-06-18 |
Bristol-Myers Squibb Company |
Agonists of ROR GAMMAt
|
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
JP7629459B2
(ja)
|
2019-11-19 |
2025-02-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
|
|
BR112022009944A2
(pt)
|
2019-11-26 |
2022-08-09 |
Bristol Myers Squibb Co |
Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
CA3162979A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted piperazine derivatives useful as t cell activators
|
|
BR112022012179A2
(pt)
|
2019-12-23 |
2022-09-06 |
Bristol Myers Squibb Co |
Compostos de quinazolina substituída úteis como ativadores de célula t
|
|
KR20220119456A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
|
|
BR112022012204A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de heteroarila substituída úteis como ativadores de célula t
|
|
KR20230020379A
(ko)
|
2020-01-06 |
2023-02-10 |
하이파이바이오 (에이치케이) 리미티드 |
항-tnfr2 항체 및 이의 용도
|
|
CN120647763A
(zh)
|
2020-01-07 |
2025-09-16 |
高诚生物医药公司 |
抗半乳糖凝集素-9抗体及其用途
|
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
CN115485302A
(zh)
|
2020-03-09 |
2022-12-16 |
百时美施贵宝公司 |
具有增强的激动剂活性的针对cd40的抗体
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
上海寻百会生物技术有限公司 |
用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
WO2022133083A1
(en)
|
2020-12-16 |
2022-06-23 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
AU2022253450A1
(en)
|
2021-04-05 |
2023-11-16 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
|
EP4320112B1
(en)
|
2021-04-06 |
2025-05-14 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
|
WO2023288254A1
(en)
|
2021-07-14 |
2023-01-19 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
|
US20240336630A1
(en)
|
2021-07-15 |
2024-10-10 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
CN119654312A
(zh)
|
2022-08-08 |
2025-03-18 |
百时美施贵宝公司 |
用作t细胞活化剂的取代的四唑基化合物
|
|
CN119677740A
(zh)
|
2022-08-09 |
2025-03-21 |
百时美施贵宝公司 |
用作t细胞活化剂的叔胺取代的双环化合物
|
|
JP2025526726A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロアゼピン誘導体
|
|
AU2023322638A1
(en)
|
2022-08-11 |
2024-11-28 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
AU2023322637A1
(en)
|
2022-08-11 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
EP4511371A1
(en)
|
2023-05-08 |
2025-02-26 |
Bristol-Myers Squibb Company |
Substituted phenyl oxazolone compounds
|
|
EP4709712A1
(en)
|
2023-05-10 |
2026-03-18 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
AU2024281056A1
(en)
|
2023-05-31 |
2026-01-22 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
AU2024285766A1
(en)
|
2023-06-07 |
2026-01-08 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
KR102834908B1
(ko)
|
2023-09-02 |
2025-07-16 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물
|
|
JP7808733B2
(ja)
|
2023-09-13 |
2026-01-29 |
ブリストル－マイヤーズ スクイブ カンパニー |
置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
TW202535865A
(zh)
|
2023-10-31 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
泛素特異性加工蛋白酶1 (usp1) 化合物
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2026035787A1
(en)
|
2024-08-07 |
2026-02-12 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) macrocyles
|
|
WO2026080794A1
(en)
|
2024-10-11 |
2026-04-16 |
Bristol-Myers Squibb Company |
Chemical compounds useful for degrading proteins
|